gene polymorphisms confer hepatoblastoma susceptibility: evidence from a seven-center case-control study.

N1-methyladenosine (mA) is a reversible epigenetic modification of RNAs. Aberrant mA modification levels due to dysregulation of mA regulators have been observed in multiple cancers. tRNA methyltransferase 10C (TRMT10C) can install mA in RNAs; however, its role in hepatoblastoma remains unknown. We conducted this study to identify causal polymorphisms in the gene for hepatoblastoma susceptibility in a cohort of Chinese children (313 cases vs. 1446 controls). The genotypes of four potential functional polymorphisms (rs7641261 C>T, rs2303476 T>C, rs4257518 A>G, and rs3762735 C>G) were determined in participants using TaqMan real-time PCR. The associations of these polymorphisms with hepatoblastoma susceptibility were estimated by logistic regression analysis adjusted for age and sex. All four polymorphisms were significantly associated with hepatoblastoma risk. In particular, under the recessive genetic model, these polymorphisms conferred an increased risk of hepatoblastoma: rs7641261 C>T [adjusted odds ratio (OR)=1.64, 95% confidence interval (CI)=1.04-2.58, =0.033], rs2303476 T>C (adjusted OR=1.87, 95% CI=1.16-3.02, =0.010), rs4257518 A>G (adjusted OR=1.45, 95% CI=1.09-1.94, =0.012), and rs3762735 C>G (adjusted OR=3.83, 95% CI=2.15-6.82, <0.0001). Combined analysis revealed that kids had an increased risk of developing hepatoblastoma if they harbored at least one risk genotype (adjusted OR=1.94, 95% CI=1.48-2.54, <0.0001). In addition, the combined risk effects of the four SNPs persisted across all the subgroups. We identified four hepatoblastoma susceptibility loci in the gene. Identifying more disease-causing loci may facilitate the development of genetic marker panels to predict individuals' hepatoblastoma predisposition.